Get the app
US › Healthcare

Artiva Biotherapeutics, Inc. Common Stock (ARTV)

US · Healthcare · Biotechnology

$8.44-1.86%
Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue
$0
Net profit
$-25.0M
EPS
$-0.63
EPS estimate
$-0.64

EPS came in at -0.63 against a street estimate of -0.64 — a beat of 1.6%.

Key statistics

Market cap
$495.7M
Forward P/E
0.0
P/B
1.44
Book value
$7.12
EPS (TTM)
$-3.23
52-week high
$14.53
52-week low
$2.22
50-day MA
$10.64
200-day MA
$7.55
Beta
2.20

Analyst view

Analysts rate Artiva Biotherapeutics, Inc. Common Stock a strong buy (6 buy, 0 hold, 0 sell out of 6) with an average price target of $35.80.

Shareholding

Insiders
14.71%
Institutions
84.17%

Largest institutional holders

FundStake
RA Capital Management, LLC20.15%
5AM Venture Management, LLC4.81%
Caligan Partners LP3.55%
VR Adviser, LLC3.29%
Samsara BioCapital, LLC1.95%
Blue Owl Capital Holdings LP1.79%
Propel Bio Management LLC1.42%
Franklin Templeton Inc1.06%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Artiva Biotherapeutics, Inc. Common Stock — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncMerck & Company IncUnitedHealth Group IncorporatedNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncNovo Nordisk A/SGilead Sciences IncAbbott Laboratories

Data updated 2026-09-18.